According to a recent study, TAS-102 (trifluridine/tipiracil; Lonsurf) provided a 31% reduction in the risk of death for patients with heavily pretreated metastatic or advanced gastric cancer that received the drug compared to patients who received a placebo. The median overall survival time was 5.7 months for patients who received TAS-102 compared with 3.6 months for patients that received the placebo. 21.2% patients survived a year following treatment compared with 13.0% of patients that received the placebo. Studies on the efficacy and safety of TAS-102 revealed that TAS-102 has a predictable and manageable safety profile.
Treatment Options
View Full Article
Related Videos